News und Analysen
![Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation
Novocure (NASDAQ: NVCR) today announced that Yoram Palti, Novocure’s Founder and Chief Technology Officer, has been selected to receive the 2022 Israel Prize in the field of entrepreneurship and
![NanoString to Showcase CosMx Spatial Molecular Imager at 4th Annual Spatial Genomics Summit, Feb. 28](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
NanoString to Showcase CosMx Spatial Molecular Imager at 4th Annual Spatial Genomics Summit, Feb. 28
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial unveiling of the CosMx™ Spatial
![Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“siRNA”) therapeutics for the
![Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq:
![Humana Earns Top Score in Human Rights Campaign Foundation’s 2022 Corporate Equality Index](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Humana Earns Top Score in Human Rights Campaign Foundation’s 2022 Corporate Equality Index
Leading health insurer and health care services company Humana Inc. (NYSE: HUM), proudly announced that it received a score of 100 on the Human Rights Campaign Foundation’s 2022 Corporate Equality
![Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), announced today that people with diabetes who are under 18 years old and require ongoing use of
![Charles River Laboratories Announces Wind Contract with Repsol for European Operations](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Charles River Laboratories Announces Wind Contract with Repsol for European Operations
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a wind energy contract with Repsol to address the entirety of the Company’s European power requirements with renewable
![Waters Earns Top Score in Human Rights Campaign Foundation’s 2022 Corporate Equality Index](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Waters Earns Top Score in Human Rights Campaign Foundation’s 2022 Corporate Equality Index
Waters Corporation (NYSE:WAT) announced that it received a score of 100 on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and
![GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220123005091/en/
Figure 1. Evolution of BCVA In LUMEVOQ®-treated
![AMN Healthcare CEO Susan Salka Recognized as One of 100 Most Influential People by Modern Healthcare](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
AMN Healthcare CEO Susan Salka Recognized as One of 100 Most Influential People by Modern Healthcare
Susan Salka, Chief Executive Officer of AMN Healthcare, was recognized by Modern Healthcare as one of the 100 Most Influential People in Healthcare for 2021, a year of unprecedented stress for
![argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211217005641/en/
Tim Van Hauwermeiren, co-founder and CEO of argenx
![AMN Healthcare Names Jorge Caballero to Board of Directors](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
AMN Healthcare Names Jorge Caballero to Board of Directors
AMN Healthcare (NYSE: AMN) today announced the Board of Directors has appointed Jorge A. Caballero as a new independent director.
This press release features multimedia. View the full release
![GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005948/en/
Figure 1. Best-Corrected Visual Acuity (BCVA) Change
![Vifor Pharma nimmt Stellung zu Medienspekulationen](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Vifor Pharma nimmt Stellung zu Medienspekulationen
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor führt mit CSL Gespräche über eine mögliche Transaktion. Entsprechende Entscheide sind noch nicht gefallen, es gibt
![Humana Foundation Names Tiffany Benjamin As Chief Executive Officer](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Humana Foundation Names Tiffany Benjamin As Chief Executive Officer
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) has announced the appointment of Tiffany Benjamin as its new Foundation CEO, effective January 3, 2022.
This press release
![AMN Healthcare Board Members Sylvia Trent-Adams and Daphne E. Jones Named to Savoy Magazine’s Most Influential Black Corporate Directors](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
AMN Healthcare Board Members Sylvia Trent-Adams and Daphne E. Jones Named to Savoy Magazine’s Most Influential Black Corporate Directors
Two members of the AMN Healthcare Board of Directors – Daphne E. Jones and Sylvia Trent-Adams -- have been named to Savoy Magazine’s prestigious 2021 list of Most Influential Black Corporate
![Agilent Announces the Cary 3500 UV-Vis Spectrophotometer Compatibility with OpenLab](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Agilent Announces the Cary 3500 UV-Vis Spectrophotometer Compatibility with OpenLab
Agilent Technologies Inc. (NYSE: A) has announced that the Agilent Cary 3500 UV-Vis Spectrophotometer is now compatible with the Agilent OpenLab software suite of products. The Cary 3500 UV-Vis
![Jazz Pharmaceuticals: Die Aktionäre können weiter tanzen!](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Jazz Pharmaceuticals: Die Aktionäre können weiter tanzen!
Auch bei Jazz Pharmaceuticals (WKN: A1JS1K) gab es gestern Abend, nachbörslich, die aktuellen Quartalszahlen. Wie hier gewohnt, fielen auch diese besser als erwartet aus.
So vermeldete das
![Epigenomics: Bald wieder frisch kapitalisiert!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Epigenomics: Bald wieder frisch kapitalisiert!
Vergangene Woche meldete die kürzlich am vorläufigen Erstattungsvorschlag der staatlichen US-Krankenversicherung "Centers for Medicare & Medicaid Services" gescheiterte Epigenomics (WKN: A11QW5)
![Astra Zeneca: Wirbel um COVID-19-Impfstoff](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Astra Zeneca: Wirbel um COVID-19-Impfstoff
AstraZeneca (WKN: 886455) teilte am Montag mit, dass die Nebenwirkungen seines potenziellen Corona-Impfstoffs bei älteren Menschen geringer seien. Die Wirkstoff-Hoffnung des britischen Pharmariesen
![Epigenomics: Jetzt droht sogar das Aus!](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Epigenomics: Jetzt droht sogar das Aus!
Erneut gibt es wenig konstruktive News, diesmal aber von Epigenomics (WKN: A11QW5) selbst. Die Gesellschaft informiert heute darüber, dass „bei pflichtmäßigem Ermessen angenommen werden muss, dass
![Aphria: Wenn das Wörtchen 'Wenn' nicht wäre...](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Aphria: Wenn das Wörtchen 'Wenn' nicht wäre...
Aphria (WKN: A12HM0), das am 17. November sein "Annual Meeting of Shareholders" veranstalten wird, erfuhr zuletzt verstärkt Investoreninteresse. Das geht zurück auf das sogenannte "ATM"-Programm
![Myokardia: Bristol-Myers Squipp setzt Einkaufstour fort...](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Myokardia: Bristol-Myers Squipp setzt Einkaufstour fort...
Zu den größten Gewinnern an den US-Aktienmärkten zählt heute die Aktie des Biotechnologieunternehmens Myokardia (WKN: A142VN). Grund hierfür ist ein Angebot, das die Aktionäre kaum ablehnen können.
![IVERIC bio: NBC-Mitglieder nehmen +41% Kursgewinn mit](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
IVERIC bio: NBC-Mitglieder nehmen +41% Kursgewinn mit
Schon 2019 hat IVERIC bio (WKN: A2PHLF) den NBC-Klingelbeutel mit sagenhaften +486% in wenigen Wochen erheblich beschwert. Nach einigen Monaten in einer Seitwärtsphase konnten Mitglieder des
![AstraZeneca: Patient erkrankt – Impfstoff-Studie gestoppt!](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
AstraZeneca: Patient erkrankt – Impfstoff-Studie gestoppt!
Rückschlag beim Corona-Impfstoff: Die britische Pharmaschmiede AstraZeneca (WKN: 886455) stoppt vorsorglich die entscheidende Studienphase. Ein Teilnehmer der UK-Studie habe Nebenwirkungen verspürt